Treatments

Peptides, longevity treatments and sexual-health medications — what each one is, whether it is FDA-approved, and what the human evidence actually supports.

How to use this section

Everything in this section is built on the same two commitments, and it is worth stating them before you read anything else.

Every price carries an evidence status. Verified means we hold a dated capture of the provider's own page. Reported — pending verification means a provider or a third party reports it and we have not captured it ourselves. Evaluation in progress means verification is pending and we are not asserting the fact. We do not upgrade a price to Verified because another comparison site published it — sites in this category contradict each other routinely, and a figure repeated by three affiliate blogs is still one unverified figure.

Every clinical claim traces to a primary source. FDA labels and guidance for regulatory status; PubMed-indexed randomised trials for efficacy; ClinicalTrials.gov for trial design. Patient forums are never used as evidence of price, safety or efficacy, and animal research is never presented as proof of a human clinical effect.

The context that applies to everything here

Three facts sit underneath every page in this section, and if you take nothing else from it, take these.

Brand prices collapsed, and most comparison sites have not updated. Brand Zepbound is now $299-$449 through LillyDirect. Brand Wegovy is $349 through NovoCare, and the oral Wegovy tablet is $149. Foundayo, Lilly's approved oral GLP-1, starts at $149. With commercial insurance that covers them, either brand can be roughly $25 a month. Against that, a compounded programme priced above $299 is charging more than the FDA-approved drug.

The legal basis for compounding these molecules narrowed sharply in 2025. The FDA declared both shortages resolved and enforcement discretion ended for every class of compounder between February and May 2025. The surviving route requires a prescriber to document a clinical difference for the individual patient — which is what "personalized dosing" and "microdose" programmes are, as a matter of regulatory mechanics rather than clinical innovation.

The trial evidence applies to injections. Every efficacy figure in this field — SURMOUNT, STEP, SELECT — comes from an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose, or an orally disintegrating tablet. The evidence is strong exactly where it was gathered and silent everywhere else.

How to verify any of this yourself

You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.

1. Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
2. Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
3. Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
4. Ask what the highest dose costs. By email or chat, so you have it in writing.
5. Ask about early cancellation before you commit to a plan longer than a month.
6. Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.

If a provider will not answer questions 4 or 5 in writing, that is itself information.

What we verify, and what we do not

Two claims on any telehealth page look identical and are not. "This provider uses a licensed pharmacy" may mean we checked a state board database, or it may mean the provider said so. Those are different epistemic states and we label them differently.

We do not upgrade a price to Verified because another comparison site published it. Sites in this category contradict each other routinely — the dataset behind this site corrected a stored TrimRx figure of $259 that matched no current tier, and an Eden brand-Zepbound figure of $299 that was actually LillyDirect's price rather than Eden's real $1,399. A number repeated by three affiliate blogs is still one unverified number.

Three facts that apply to everything in this section

Brand prices collapsed, and most comparison pages have not updated. Brand Zepbound is $299-$449 through LillyDirect. Brand Wegovy is $349 through NovoCare, and the oral Wegovy tablet is $149. Foundayo, Lilly's approved oral GLP-1, starts at $149. With commercial coverage either brand can be roughly $25 a month. Against that, a compounded programme priced above $299 is charging more than the FDA-approved drug — and several are.

The legal basis for compounding narrowed sharply in 2025. The FDA declared both shortages resolved and enforcement discretion ended for every class of compounder between February and May 2025. The surviving route requires a prescriber to document a clinical difference for the individual patient — which is what "personalized dosing" and "microdose" programmes are, as a matter of regulatory mechanics rather than clinical innovation.

The trial evidence applies to injections. Every efficacy figure in this field — SURMOUNT, STEP, SELECT — comes from an FDA-approved subcutaneous injection. None of it was collected on a compounded preparation, a microdose, or an orally disintegrating tablet. The evidence is strong exactly where it was gathered and silent everywhere else, and the gap between those two things is where most of the marketing in this industry operates.

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

1. Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
3. In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
4. What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
5. Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
6. Will you provide a certificate of analysis?
7. Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.

The pattern to watch for